These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28759228)

  • 1. Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.
    Mikami S; Sasaki S; Asano Y; Ujikawa O; Fukumoto S; Nakashima K; Oki H; Kamiguchi N; Imada H; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7658-7676. PubMed ID: 28759228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor for the Treatment of Cognitive Disorders.
    Mikami S; Nakamura S; Ashizawa T; Nomura I; Kawasaki M; Sasaki S; Oki H; Kokubo H; Hoffman ID; Zou H; Uchiyama N; Nakashima K; Kamiguchi N; Imada H; Suzuki N; Iwashita H; Taniguchi T
    J Med Chem; 2017 Sep; 60(18):7677-7702. PubMed ID: 28796496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a Novel Series of Pyrazolo[1,5-a]pyrimidine-Based Phosphodiesterase 2A Inhibitors Structurally Different from N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (TAK-915), for the Treatment of Cognitive Disorders.
    Mikami S; Kawasaki M; Ikeda S; Negoro N; Nakamura S; Nomura I; Ashizawa T; Kokubo H; Hoffman ID; Zou H; Oki H; Uchiyama N; Hiura Y; Miyamoto M; Itou Y; Nakashima M; Iwashita H; Taniguchi T
    Chem Pharm Bull (Tokyo); 2017; 65(11):1058-1077. PubMed ID: 29093293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.
    Helal CJ; Arnold EP; Boyden TL; Chang C; Chappie TA; Fennell KF; Forman MD; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; Mente S; O'Connor RE; Pandit J; Piotrowski M; Schmidt AW; Schmidt CJ; Ueno H; Verhoest PR; Yang EX
    J Med Chem; 2017 Jul; 60(13):5673-5698. PubMed ID: 28574706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [1,2,4]Triazolo[1,5-
    Tresadern G; Velter I; Trabanco AA; Van den Keybus F; Macdonald GJ; Somers MVF; Vanhoof G; Leonard PM; Lamers MBAC; Van Roosbroeck YEM; Buijnsters PJJA
    J Med Chem; 2020 Nov; 63(21):12887-12910. PubMed ID: 33105987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models.
    Nakashima M; Suzuki N; Shiraishi E; Iwashita H
    Behav Brain Res; 2019 Dec; 376():112192. PubMed ID: 31521738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.
    Redrobe JP; Jørgensen M; Christoffersen CT; Montezinho LP; Bastlund JF; Carnerup M; Bundgaard C; Lerdrup L; Plath N
    Psychopharmacology (Berl); 2014 Aug; 231(16):3151-67. PubMed ID: 24577516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 2A inhibitor, PDM-631.
    Maehara S; Arakawa K; Hoshida K; Nagasue H; Chida N; Nakao K; Furusako S
    Eur J Pharmacol; 2017 Sep; 811():110-116. PubMed ID: 28587776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Novel Phosphodiesterase-2A Inhibitors by Structure-Based Virtual Screening, Structural Optimization, and Bioassay.
    Zhang C; Feng LJ; Huang Y; Wu D; Li Z; Zhou Q; Wu Y; Luo HB
    J Chem Inf Model; 2017 Feb; 57(2):355-364. PubMed ID: 28055196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
    Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
    J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study.
    Kumar J; Umar T; Kausar T; Mobashir M; Nayeem SM; Hoda N
    J Mol Model; 2017 Jan; 23(1):7. PubMed ID: 27966018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, 18F-Radiolabelling and Biological Characterization of Novel Fluoroalkylated Triazine Derivatives for in Vivo Imaging of Phosphodiesterase 2A in Brain via Positron Emission Tomography.
    Schröder S; Wenzel B; Deuther-Conrad W; Teodoro R; Egerland U; Kranz M; Scheunemann M; Höfgen N; Steinbach J; Brust P
    Molecules; 2015 May; 20(6):9591-615. PubMed ID: 26016549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of phosphodiesterase (1B, 2A, 9A and 10A) inhibitors on central nervous system cyclic nucleotide levels in rats and mice.
    Chen J; Zook D; Crickard L; Tabatabaei A
    Neurochem Int; 2019 Oct; 129():104471. PubMed ID: 31121256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
    Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
    Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of polycyclic pyrazolo[3,4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors.
    Xia Y; Chackalamannil S; Czarniecki M; Tsai H; Vaccaro H; Cleven R; Cook J; Fawzi A; Watkins R; Zhang H
    J Med Chem; 1997 Dec; 40(26):4372-7. PubMed ID: 9435906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
    Raheem IT; Breslin MJ; Fandozzi C; Fuerst J; Hill N; Huszar S; Kandebo M; Kim SH; Ma B; McGaughey G; Renger JJ; Schreier JD; Sharma S; Smith S; Uslaner J; Yan Y; Coleman PJ; Cox CD
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5903-8. PubMed ID: 22892116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel PDE2A reporter cell line: characterization of the cellular activity of PDE inhibitors.
    Wunder F; Gnoth MJ; Geerts A; Barufe D
    Mol Pharm; 2009; 6(1):326-36. PubMed ID: 19049345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphodiesterase 2A localized in the spinal cord contributes to inflammatory pain processing.
    Kallenborn-Gerhardt W; Lu R; Bothe A; Thomas D; Schlaudraff J; Lorenz JE; Lippold N; Real CI; Ferreirós N; Geisslinger G; Del Turco D; Schmidtko A
    Anesthesiology; 2014 Aug; 121(2):372-82. PubMed ID: 24758774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.
    Helal CJ; Arnold E; Boyden T; Chang C; Chappie TA; Fisher E; Hajos M; Harms JF; Hoffman WE; Humphrey JM; Pandit J; Kang Z; Kleiman RJ; Kormos BL; Lee CW; Lu J; Maklad N; McDowell L; McGinnis D; O'Connor RE; O'Donnell CJ; Ogden A; Piotrowski M; Schmidt CJ; Seymour PA; Ueno H; Vansell N; Verhoest PR; Yang EX
    J Med Chem; 2018 Feb; 61(3):1001-1018. PubMed ID: 29293004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
    Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
    J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.